
Conference Coverage
about 1 month ago
Cefiderocol Shows Activity Against Difficult-to-Treat Pathogensabout 2 months ago
Does Where People Live Affect Antibiotic Prescribing Practices?about 2 months ago
Considering Alternatives to Vancomycin for MRSALatest Content

Jan 09, 2026 | News
Unlocking New Defenses: The Changing Landscape of Candida auris Management

What's New in 2025: From the CLSI Subcommittee on Antimicrobial Susceptibility Testing
Jan 09, 2026

Training Healthcare Professionals to Treat High-Consequence Infectious Disease
Jan 08, 2026

A Dose of Clarity: Low- vs High-Dose Trimethoprim-Sulfamethoxazole for Stenotrophomonas maltophilia Pneumonia
Jan 08, 2026

The Great Debate: To Extend or Not Extend?
Jan 07, 2026

Advertisement
Shorts

0:39
Challenges of Acquiring Phage Therapy
2 months ago
by
Ashlan Kunz Coyne, PharmD, MPH(+1 more)

0:48
Building Parents' Trust About Childhood Vaccines
2 months ago
by
Ruth Lynfield, MD(+1 more)

0:14
A Monoclonal Antibody as a COVID-19 Alternative
2 months ago
by
Robert Allen, PhD(+1 more)

0:36
Vaccines as a Secondary Strategy in the Fight Against Antimicrobial Resistance
3 months ago
by
Barry Kreiswirth, PhD(+1 more)

0:36
The Center for Discovery and Innovation’s Commitment to Fungal Diagnostics and Treatment
3 months ago
by
David Perlin, PhD(+1 more)

0:41
Kevin Ault, MD on ACIP Shared Decision-Making, Informed Consent, and Vaccine Policy
4 months ago
by
Kevin Ault, MD(+1 more)

0:52
Adoption of Rapid Diagnostic Tools, Susceptibility Testing for Gram-Negative Infections
4 months ago
by
Rodney E. Rohde, PhD, MS, SM(ASCP)CM, SVCM, MBCM, FACSc; and Ryan P. McNamara, PhD(+1 more)

0:26
Why Intestinal Antibodies Are Key to Beating Norovirus Infection
4 months ago
by
Sean N Tucker, PhD(+1 more)

0:22
Examining Chronic Chikungunya and Potential Clues to Rheumatologic Symptoms
4 months ago
by
Daniela Weiskopf, PhD(+1 more)

0:28
Clinical Considerations for Using Newer Antibiotics for Gram-Negative Infections
4 months ago
by
Ryan K. Shields, PharmD, MS(+1 more)
Podcasts
Videos
Contagion Digital Edition

The subcommittee approved the removal of doxycycline and tetracycline breakpoints and revised aminoglycoside breakpoints for Acinetobacter spp, and added aztreonam-avibactam breakpoints for Enterobacterales.

A recent study challenges the need for high-dose trimethoprim-sulfamethoxazole in managing Stenotrophomonas maltophilia pneumonia, finding lower doses may offer comparable efficacy.

A recent study examined how rurality and the availability of post discharge follow-up influence clinicians’ decisions on antibiotic duration at discharge for patients hospitalized with community-acquired pneumonia.

A series of politically driven actions in 2025—including defunding mRNA research, dismantling vaccine advisory bodies, and restricting CDC recommendations—has undermined US vaccine access and pandemic preparedness, but professional societies and some states are stepping in to preserve evidence-based public health.

The NARROWS framework, developed within the IDSA Core Antimicrobial Stewardship Curriculum, provides a structured, behaviorally informed approach to communication that helps stewardship teams address the social, emotional, and cultural factors influencing prescribing decisions in order to optimize antimicrobial use and combat resistance.

Stenotrophomonas maltophilia is an opportunistic, multidrug-resistant pathogen that poses significant treatment challenges due to its complex resistance mechanisms, limited therapeutic options, and high mortality rates among vulnerable patients.

This review highlights how people living with HIV are living longer due to antiretroviral therapy but face unique age-related health challenges, including cardiovascular disease, metabolic syndrome, renal dysfunction, neurocognitive decline, immunosenescence, bone loss, and frailty, requiring tailored screening and management strategies.

Biosurveillance is an essential early warning system for detecting and responding to infectious disease threats, helping to prevent localized cases from becoming widespread outbreaks or pandemics. Despite its proven value during crises such as COVID-19, biosurveillance programs often suffer from inconsistent funding and support, underscoring the urgent need for sustained investment and integration into public health infrastructure.

Clinical trial and real-world data, including the PROVE study, support its role as an effective and carbapenem-sparing therapy for serious infections, though outcomes vary depending on pathogen and infection type.































































































